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Human exposure to Anopheles farauti 
bites in the Solomon Islands is not associated 
with IgG antibody response to the gSG6 salivary 
protein of Anopheles gambiae
Edgar J. M. Pollard1, Catriona Patterson2, Tanya L. Russell1, Alan Apairamo3, Jance Oscar3, Bruno Arcà4, 
Chris Drakeley2 and Thomas R. Burkot1* 
Abstract 
Background: Mosquito saliva elicits immune responses in humans following mosquito blood feeding. Detection 
of human antibodies recognizing the Anopheles gambiae salivary gland protein 6 (gSG6) or the gSG6-P1 peptide in 
residents of Africa, South America and Southeast Asia suggested the potential for these antibodies to serve as a uni-
versal marker to estimate human biting rates. Validating the utility of this approach requires concurrent comparisons 
of anopheline biting rates with antibodies to the gSG6 protein to determine the sensitivity and specificity of the assay 
for monitoring changes in vector populations. This study investigated whether seroprevalence of anti-gSG6 antibod-
ies in humans reflected the relative exposure to Anopheles farauti bites in the Solomon Islands as estimated from 
sympatric human landing catches.
Methods: Human biting rates by An. farauti were estimated by landing catches at 10 sampling sites in each of 4 
villages during the wet and dry seasons. Human serum samples from these same villages were also collected during 
the wet and dry seasons and analysed for antibody recognition of the gSG6 antigen by the Luminex  xMAP© platform. 
Antibody titres and prevalence were compared to HLCs at the sampling sites nearest to participants’ residences for 
utility of anti-gSG6 antibodies to estimate human exposure to anopheline bites.
Results: In this study in the Solomon Islands only 11% of people had very high anti-gSG6 antibody titres, while other 
individuals did not recognize gSG6 despite nightly exposures of up to 190 bites by An. farauti. Despite clear spatial 
differences in the human biting rates within and among villages, associations between anti-gSG6 antibody titres and 
biting rates were not found.
Conclusions: Few studies to date have concurrently measured anopheline biting rates and the prevalence of human 
antibodies to gSG6. The lack of association between anti-gSG6 antibody titres and concurrently measured human 
biting rates suggests that the assay for human anti-gSG6 antibodies lacks sufficient sensitivity to be a biomarker of An. 
farauti exposure at an epidemiologically relevant scale. These findings imply that an improvement in the sensitivity of 
serology to monitor changes in anopheline biting exposure may require the use of saliva antigens from local anophe-
lines, and this may be especially true for species more distantly related to the African malaria vector An. gambiae.
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Background
As malaria transmission diminishes, endemic areas 
become stratified with foci of residual transmis-
sion appearing, based on receptivity, vulnerability 
and access and use of malaria prevention strategies 
[e.g., long-lasting insecticide-treated nets (LLINs) 
and indoor residual spraying (IRS)] [1, 2]. Defining 
foci and receptivity becomes increasingly challeng-
ing in areas with small vector populations. The classic 
entomological measure of transmission intensity, the 
entomological inoculation rate (EIR), requires estimat-
ing two parameters (the biting rate and the sporozo-
ite rate), both of which can vary widely and rapidly in 
time and space. Hence, the EIR best estimates trans-
mission intensity in high malaria transmission settings 
with high mosquito biting populations [3, 4]. Due to 
the lack of precision in estimating sporozoite rates in 
low-transmission settings, vector biting rates remain 
the best entomological proxy to estimate receptivity 
despite the logistical challenges associated with spa-
tial–temporal heterogeneity in biting rates [5].
Recently, human antibodies recognizing the Anoph-
eles gambiae salivary protein gSG6 [6] or the gSG6-
P1 peptide [7] were shown to be associated with 
recent exposure to anopheline bites in tropical Africa 
[8, 9]. A similar, although weaker, association was 
later documented in a number of geographic areas, 
including South America and Southeast Asia where 
other anopheline species are responsible for malaria 
transmission [10, 11]. In the South Pacific nation of 
Vanuatu, seroprevalence to gSG6 was correlated to 
reactivity to Plasmodium falciparum and Plasmodium 
vivax antigens, which was hypothesized to be related 
to exposure to the bites of Anopheles farauti, but bit-
ing rates were not estimated [12]. These observations 
suggested that anti-gSG6 antibody levels or seroprev-
alence might serve as an entomological proxy to esti-
mate anopheline biting intensity by reflecting recent 
exposure to anopheline bites [8]. This approach has 
advantages compared to estimating biting rates by 
mosquito counts, as antibody prevalence would be less 
affected by short-term fluctuations in transmission 
intensity relative to estimates of the number of biting 
mosquitoes and would therefore be more cost effective 
and potentially more precise.
In the Western Province of the Solomon Islands, 
malaria transmission is heterogeneous with a wide 
range in An. farauti biting rates documented [5]. The 
potential of anti-gSG6 antibodies to be a biomarker 
of human exposure to An. farauti bites in the Western 
Province, Solomon Islands was investigated.
Methods
Mosquito and human blood surveys took place during 
the dry and wet seasons in the villages of Jack Harbour, 
Tuguivili, Saeragi, and New Mala in Western Province, 
Solomon Islands [5, 13]. Human biting rates were esti-
mated twice in the dry season (May and August 2016) 
and twice in the wet season (November 2016 and Febru-
ary 2017). Because An. farauti biting densities are het-
erogeneous within and among villages, biting rates were 
estimated by human landing catches (HLC) at 10 loca-
tions (stations) within each village from 18:00 to 00:00 h. 
During this period, 93% of bites by An. farauti occurs 
[14]. Hence, this collection period closely approximates 
the number of bites by An. farauti nightly and will be 
referred to hereafter as the nightly biting rate. During 
each village vector survey, sampling was conducted for 
four nights at each of 10 sampling locations (Fig. 1). The 
mosquitoes were identified morphologically in the field 
[15] and then a sub-sample was further identified by PCR 
amplification of the internal transcribed spacer region 2 
of the ribosomal DNA for molecular confirmation of spe-
cies [16].
Human blood surveys were conducted in Septem-
ber 2016 and March 2017. After explaining the purpose 
of the survey, including potential risks, blood samples 
were taken from all individuals providing written con-
sent (consent for individuals < 18  years was provided by 
a b
c d
Fig. 1 Proximity of stations where Anopheles farauti biting rates were 
estimated by human landing catch to households of individuals 
providing serum are shown for the villages of New Mala (a), Jack 
Harbour (b), Tuguivili (c) and Saeragi (d)
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a parent or guardian). Demographic data (name, age, 
gender, house location, travel history, anti-malaria, and 
bed-net use histories) were recorded prior to collection 
of blood samples by finger prick. Samples were allowed 
to clot before centrifugation to separate serum. Serum 
was removed and transferred into 2-mL micro-vials 
labelled with a unique identifying number. Sera was ini-
tially stored at 4 °C, and within 4 days moved to a central 
location and frozen before shipping on dry ice with sub-
sequent storage at ‒ 80 °C.
Anti-gSG6 antibody titres were measured using an 
IgG detection quantitative suspension bead array on 
the Luminex  xMAP© platform (Luminex Corp, Austin, 
TX, USA) alongside a panel of P. falciparum (PfAMA1, 
PfMSP119 and GLURP2)- and P. vivax (PvAMA1 
and PvMSP1-19)-derived recombinant antigens. The 
Luminex assay for gSG6 antibodies was optimized 
by testing a range of gSG6 concentrations coupled to 
Luminex microspheres against 4 control pools for reac-
tivity, specificity and optimal coupling concentration. 
Assay conditions were validated against serum samples 
from Burkina Faso with high and low mosquito bite expo-
sure along with British negative controls and malaria-
positive controls. Serum dilutions of 1:200 were used in 
subsequent assays to minimize background cross-reac-
tivity with an optimal concentration of 18.28  μg/mL of 
gSG6-P1 coupled to microsphere beads.
Diluted samples (1:200) were co-incubated with gSG6-
coated microspheres, and after washing, a detection anti-
body was added followed by a final wash. The median 
fluorescent intensity (MFI) emitted by a reporter mol-
ecule on the detection antibody was measured using a 
Luminex  MAGPIX© analyzer. All antigens underwent 
pre-assay optimization to identify a coating concentra-
tion that captured a dynamic range of responses [17]. 
Control sera consisted of hyperimmune serum samples 
to P. falciparum and P. vivax, and British malaria-naïve 
individuals.
Positives, negatives and blanks were present on each 
plate and compared to each other and pre-existing data 
to test for variability and accuracy. The positive control 
panel consisted of 10/198 (WHO P. falciparum positive 
reference standard curve), two duplicate wells of CP3 (a 
P. falciparum positive pool sourced from hyperimmune 
Tanzanian individuals) and two duplicate wells of 72/96 
(a P. vivax positive control) at 1:200 dilutions. Negative 
controls consisted of 4 malaria-naive samples per plate 
(from a panel of 40 samples provided by Public Health 
England). Two wells of each plate contained only dilution 
buffer to test for background reactivity. A seropositive 
sample was defined as having an MFI value greater than 
the mean value of the negative samples plus three stand-
ard deviations.
The dataset was analysed by pairing individual gSG6 
antibody MFI values with biting rate estimations based 
on the locations of individuals’ home residences as 82% of 
exposure to biting An. farauti occurs either in the home 
or the adjacent peri-domestic area (Pollard et  al. sub-
mitted). Each participant providing a blood sample was 
assigned an anopheline biting rate based on the mean 
nightly HLC of the nearest HLC station to that individ-
ual’s house. Participants living more than 100  m from 
an HLC station were excluded in the analyses for asso-
ciations between biting rates and antibodies to gSG6. The 
relationship between biting exposure (estimated from 
HLC) and antibody titres was analysed using Spearman’s 
rank correlation. The differences in biting rates between 
villages and seasons were analysed using generalized lin-
ear models (GLM). The difference between the gSG6 MFI 
values for each village was analysed using a GLM with the 
British control group as the reference. For the residents 
that provided serum during both the dry and wet season, 
a paired dataset was constructed and the change in the 
gSG6 antibody MFI values over time was compared with 
a Wilcoxon signed ranked test. Statistical analysis was 
conducted using R statistical software (ver. 3.1.2).
Results
A total of 10,110 female anophelines were sampled dur-
ing 660 HLC collections at 10 stations in each of 4 vil-
lages (Fig.  1). Species identification was confirmed by 
PCR in a sample of 630; 95% of the confirmed species 
identifications were An. farauti (601 of 630), 3.5% were 
Anopheles hinesorum (22 of 630) and 1% were Anoph-
eles lungae (7 of 630). The mean biting rate of An. far-
auti varied significantly by village (Table 1; β = 24.740, 
se = 1.1216, p < 0.0001) and season (β = 6.4063, 
se = 1.1917, p < 0.0001). The average nightly biting rate 
of anophelines during the dry season across all 4 vil-
lages was 6.5 compared to an average of 19.0 during the 
wet season. Highest biting rates were in Jack Harbour, 
Table 1 The mean and  range in  Anopheles farauti human 
landing rates from  10 sampling sites within  each village 
during 4 surveys
Season Date Village [mean (range)]
Jack Harbour New Mala Saeragi Tuguivili
Dry May 2016 44.0 (7–120) 2.7 (0–14) 0.2 (0–2) 1.8 (0–8)
Aug 2016 1.1 (0–6) 1.8 (0–10) 0.1 (0–2) 0.3 (0–4)
Wet Nov 2016 67.4 (0–367) 0.2 (0–3) 0 (0–0) 12.9 (0–73)
Feb 2017 64.6 (2–279) 0.6 (0–4) 0 (0–0) 6.7 (0–26)
Mean 47.7 1.2 0.1 5.7
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where only An. farauti was found. Mean biting rates 
among 10 sampling stations in Jack Harbour ranged to 
190 (Table 1).
A total of 791 serum samples were collected from 
residents of the 4 villages. From each village, Jack Har-
bour, New Mala, Saeragi, and Tuguivili, the number of 
samples collected in the dry season (September 2016) 
were 74, 117, 110, and 85, respectively; and in the wet 
season (March 2017) were 69, 137, 83, and 116, respec-
tively. Overall, a total of 210 samples were paired being 
collected from the same 105 residents during the dry 
season and again in the wet season.
Typical age-specific patterns of long-term exposure 
markers, PfAMA1, PfMSP1-19, GLURP2, PvAMA1 and 
PvMSP1-19 were observed for the serum samples from 
the Solomon Islands (results for PfMSP1-19 shown in 
Fig.  2), confirming the assay performed as expected 
for the parasite antigens. When gSG6 MFI values were 
analysed by age categories (< 5, 6–15 and > 16  years), 
no significant association was seen (Fig.  3; β = ‒ 18.35, 
se = 22.32, p = 0.411). The gSG6 responses of the neg-
ative control panel of 40 malaria-naïve samples fell 
within a range of the mean plus three standard devia-
tions (MFI value of 253).
Estimates of mean An. farauti bite exposures of indi-
viduals were based on HLCs at the nearest mosquito 
collection station to an individual’s house (Fig. 1). Par-
ticipants living within 100  m of the nearest mosquito 
collection station (n = 733 samples) were included in 
the analyses for associations between biting rates and 
antibodies to gSG6. The mean distance from houses to 
closest HLC station for participants was 29  m (mean 
distances by village were 23 m, 36 m, 33 m, and 25 m 
in Jack Harbour, New Mala, Saeragi and Tuguivili, 
respectively).
Sera from 11% of 791 samples were classified as sero-
positive to gSG6. A significant relationship between the 
prevalence of anti-gSG6 antibody MFI and intensity of 
exposure to An. farauti bites in the month preceding 
blood surveys was not found (Fig. 4) (ρ = 0.0276, p = 0.4). 
In fact, residents with high nightly An. farauti exposure 
Fig. 2 Age-specific patterns of long-term Plasmodium falciparum 
exposure of residents in Western Province of the Solomon Islands 
represented by a scatter plot of log-transformed antibody PfMSP1-19 
median fluorescence index (MFI) by age with loess regression line 
(red line)
Fig. 3 Age-specific patterns of gSG6 MFI recognition for serum 
of residents of Western Province in the Solomon Islands (sample 
sizes: < 5 years, n = 98; 6–15 years, n = 260; > 16 years, n = 424). 
Differences in mean gSG6 MFI reactivity by age were not significantly 
different
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Fig. 4 The relationship between the intensity of anti-gSG6 antibody 
responses and exposure to the mean number of Anopheles farauti 
bites per person per half-night estimated from the nearest collection 
station to participants homes during the month preceding blood 
surveys
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(> 10 bites) did not generate high levels of antibody 
titres: the highest gSG6 MFI value observed was 634 
for individuals exposed to high biting rates, while resi-
dents exposed to more moderate biting rates (< 10 bites/
night) had gSG6 MFI values ranging up to 4897. Analy-
ses comparing the prevalence of anti-gSG6 antibody MFI 
and intensity of exposure to An. farauti bites in both the 
wet and dry seasons as the mean of HLCs in surveys 
one and four months preceding each blood survey also 
did not reveal any significant relationships (ρ = ‒ 0.0702, 
p = 0.05).
Differences in the population level antibody titres for 
each village were analysed both in the dry and wet sea-
sons using the British population as a reference group 
(Fig. 5). There were only two Solomon Island populations 
(Tuguivili village during both the dry and wet seasons 
when nightly biting rates were 0.3 and 6.7) that were sta-
tistically different from the British control serum sam-
ples (p = 0.022 and p = 0.002). In the other villages, MFI 
values were not significantly different from the British 
controls, including Jack Harbour village with an almost 
tenfold greater nightly number of biting An. farauti than 
Tuguivili village (Fig. 5).
Overall, significant differences in the mean MFI to 
gSG6 of all serum samples between the dry and wet 
seasons were not found. However, when paired sera of 
individuals (n = 105) from the dry and wet seasons were 
compared, there was a slight but significant increase in 
MFI values to gSG6 from the dry (mean = 189) to the 
wet season (mean = 202.9) (Wilcoxon signed ranked 
test: V = 1982.5, p = 0.01542). The MFI values to gSG6 of 
residents of Jack Harbour showed a significant increase 
between the dry and wet seasons, increasing from a mean 
of 74.08 to 125.8 (Wilcoxon signed ranked test: V = 17, 
p = 0.0001) when the mean nightly An. farauti biting 
rates in the dry and wet seasons increased from 22.5 to 
66.5 (based on the mean of two vector surveys for HLC 
preceding the blood survey).
Discussion
An association between human anti-gSG6 antibody titres 
(expressed as MFI values) and exposure to An. farauti 
bites as determined by HLCs was not observed in this 
study. While some individual serum samples strongly rec-
ognized gSG6, the reactivity of most serum samples from 
the malaria-endemic Solomon Islands were not signifi-
cantly greater than the British negative controls. Failure 
to find significant recognition of anti-gSG6 antibodies in 
the majority of residents tested could be due to epidemi-
ological factors (e.g., inadequate exposure to An. farauti 
bites, or variations in the attractiveness of individuals to 
An. farauti not captured by the estimates of human biting 
rates) or immunological effects (e.g., limited understand-
ing of the kinetics of the anti-gSG6 response in humans, 
inadequate assay sensitivity or insufficient similarity of 
saliva antigens of An. farauti to the gSG6 antigen of An. 
gambiae). Previous studies indicated that antibody lev-
els and/or seroprevalence to vector salivary antigens can 
reliably estimate malaria transmission in a number of 
countries, especially in tropical Africa (i.e., seropreva-
lence to gSG6 or gSG6-P1 and malaria antigen mark-
ers are significantly associated). However, validating the 
IgG response to gSG6 as a reliable marker of mosquito 
exposure requires comparing human antibody reactivity 
to gSG6-P1 or to gSG6 with estimates of mosquito biting 
rates on the same individuals or by comparing the reac-
tivity of populations in defined areas with estimates of 
biting rates in the same areas, as was done in Senegal and 
Cambodia using single estimates of biting rates for each 
census district or village, respectively [9, 18]. In this study 
in the Solomon Islands, biting rates within villages were 
determined at 10 locations per village by HLCs to esti-
mate the exposure of residents of nearest houses to biting 
mosquitoes.
In Cambodia, despite a ninefold range in the size of 
Anopheles dirus populations between two villages, little 
difference was seen in the corresponding antibody recog-
nition of gSG6 [18]. In this study, a greater than 100-fold 
range in exposures to An. farauti bites was documented 
amongst 4 villages without finding an association with 
the titre or prevalence of antibodies to the gSG6 antigen.
Previous work in Senegal found an association 
between antibody prevalence to whole An. gambiae 
saliva or to the gSG6-P1 peptide and An. gambiae 
Fig. 5 The relationship between the intensity of anti-gSG6 MFI 
antibody responses of individuals by estimated An. farauti biting 
rates from the biting surveys a month before the blood survey. 
Seropositives were defined as sera generating an MFI greater than 
the mean plus three standard deviations of the MFI values from 
40 malaria naïve British (shown as blue). Seropositive cut-off line is 
shown as a red dashed line. Significantly different mean MFI values 
(at the 002 level) of participants of villages are identified by different 
letters above the village specific MFI values. Significantly elevated MFI 
values relative to British sera were found in two village surveys when 
biting rates were low (0.3 bites/night) and high (6.7 bites/night)
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nightly biting rates up to 124 [9, 19]. This biting inten-
sity is comparable to the nightly exposure of people 
to An. farauti bites in the high exposure village in this 
study (191 bites/person). While a minority of individu-
als had a wide range in seropositive antibody titres 
recognizing gSG6 in the Solomon Islands, most indi-
viduals (89%) were seronegative. Amongst the 11% of 
individuals who were seropositive, significant associa-
tions with An. farauti bite exposure were not seen. In 
Vanuatu where An. farauti is also the primary vector, 
a decrease in seroprevalence to gSG6 with malaria 
transmission was correlated to reactivity to P. falcipa-
rum and P. vivax antigens [12]. A significant difference 
between the study in Vanuatu and this study in the 
Solomon Islands was that the An. farauti biting rates in 
Vanuatu were not estimated entomologically whereas 
the biting rates in the Solomon Islands were estimated 
at a fine scale enabling specific estimates of the expo-
sure of individuals to biting An. farauti with the inten-
sity of antibody recognition of gSG6 by those same 
individuals.
These results could be explained in part by a lack of 
assay sensitivity, as hypothesized by the studies in Cam-
bodia [18] and Vanuatu [12]. Previous studies employed 
gSG6-P1 or gSG6 as antigens with sera diluted from 
1:20 to 1:200. The studies in Cambodia and Vanuatu 
measured responses in an ELISA to 5 µg/mL gSG6 at a 
serum dilution of 1:200. This study also measured anti-
body responses of serum diluted 1:200 to gSG6, but in 
a Luminex platform. While anti-gSG6 antibody preva-
lence may be lower due to the serum concentration 
used in the assays (1:200), any relationship between 
exposure to high levels of anopheline bites and cor-
responding highly reactive sera to gSG6 should still 
have been evident. Furthermore, a typical age-related 
increase in antibodies to specific malaria antigens was 
observed in this study in the Solomon Islands suggest-
ing the assay performed as expected. A lack of age-
related antibody response for gSG6 was observed in 
Burkina Faso but was hypothesized to be immune tol-
erance generated after intense and prolonged exposure 
to bites of Afrotropical malaria vectors [20, 21].
Another plausible explanation for the lack of associa-
tion between anti-gSG6 antibodies and An. dirus bit-
ing rates in Cambodia [18] and in this study with An. 
farauti may be the limited sequence homology between 
An. gambiae and both An. dirus and An. farauti SG6 
proteins. The An. gambiae gSG6 (used as antigen in all 
reported studies) shares only 54 and 52% identity with 
An dirus and An. farauti SG6 proteins, the primary 
malaria vectors in Cambodia and the Solomon Islands, 
respectively [22]. The limited similarity (70%) to An. 
farauti gSG6 was hypothesized as likely responsible for 
a low assay sensitivity in the Vanuatu study [12].
In the study in the Americas, antibody recognition of 
the gSG6-P1 antigen was reported as significantly cor-
related with malaria infection status and mosquito bite 
exposure history of Columbians and Chilians [10]. In 
that study, residents of Columbia may have been exposed 
to the bites of the main malaria vectors, Anopheles albi-
manus, Anopheles darlingi and Anopheles punctimac-
ula; Chilean soldiers stationed in Haiti would have been 
potentially exposed to An. albimanus, the only malaria 
vector in Haiti. However, the SG6 antigen is absent in 
both An. albimanus and An. darlingi as well as in all 
other species belonging to the Nyssorhynchus sub-genus 
analysed [22, 23], suggesting that the antibodies to gSG6 
in Columbians may represent exposure to An. puncti-
macula (a member of the Anopheles sub-genus) or minor 
vectors. For the Chilean soldiers, previous exposure to 
anopheline bites in Chile, including Anopheles pseu-
dopunctipennis (also belonging to the Anopheles sub-
genus), may have generated the antibody recognition of 
gSG6 [24]. While Anopheles atacamensis and Anopheles 
pictipennis are also endemic to Chile [25], these species 
are in the same sub-genus (Nyssorhynchus) as An. albi-
manus or An. darlingi which lack the SG6 protein coding 
gene [22, 23].
The use of antibodies against anopheline salivary pro-
teins as markers of human exposure to malaria vectors 
has multiple advantages over longitudinal collections of 
anophelines by HLCs; in fact, serological analyses are 
both faster (requiring a single cross-sectional survey to 
estimate recent exposure to biting mosquitoes) and less 
expensive while minimizing exposure of survey teams to 
anophelines bites.
In the Southwest Pacific where An. farauti is the domi-
nant vector, a number of challenges to using and inter-
preting antibody recognition of the gSG6 antigen as a 
proxy for measuring biting exposure were identified 
that limits the potential of this assay for programme or 
research applications. Firstly, the overall low reactivity 
of most sera of Solomon Islands residents to gSG6 will 
require large numbers of serum samples to detect sig-
nificant changes in biting intensity. Consequently, the 
assay will not be applicable for monitoring small-scale 
heterogeneities in biting rates (a feature of low transmis-
sion scenarios in general and in the Southwest Pacific 
in particular [5, 26]. Secondly, finding highly reactive 
serum in villages with very low An. farauti biting rates 
and, conversely, unreactive serum in village residents 
with very high biting rates is perplexing. This will require 
well-characterized studies to compare serum reactivity 
to saliva antigen with concurrent biting rates to under-
stand the relationship between bite exposure and the 
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development (and loss) of antibodies to saliva antigens 
to allow epidemiologically relevant interpretations of 
changes in the prevalence and intensity of antibody rec-
ognition of saliva antigens.
Conclusion
Despite the fact that significant levels of anti-gSG6 anti-
bodies were not found in individuals exposed to sig-
nificant numbers of An. farauti bites in this study, the 
potential utility of human antibodies as markers of biting 
exposure shows great promise. However, as pointed out 
by the results reported here, the use of anopheline sali-
vary antigens as a proxy for estimating human exposure 
to bites of malaria vectors may require the use of salivary 
antigens from local mosquito species and validation by 
correlation of antibody reactivity with concurrent ento-
mological measurements.
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